PGNX Progenics Pharmaceuticals Inc.

4.99
-0.02  -0%
Previous Close 5.01
Open 5.01
Price To Book 7.68
Market Cap 431,243,954
Shares 86,421,634
Volume 755,437
Short Ratio
Av. Daily Volume 1,120,766
Stock charts supplied by TradingView

NewsSee all news

  1. Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer,

  2. Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer

    NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer,

  3. Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ("Progenics" or the "Company"), an oncology company developing innovative targeted medicines and artificial intelligence to

  4. Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board

    Progenics Stockholders Consent to Removal of CEO Mark Baker, Dr. David Scheinberg and Nicole Williams and Election of All Five Velan Nominees – Gérard Ber, Eric Ende, Ann MacDougall, Heinz Mäusli and David Mims Velan

  5. Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

    Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical TherapeuticsAZEDRA Commercial Dosing

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due by end of 2019.
PyL
Prostate cancer
FDA approval announced July 30, 2018.
Azedra
Pheochromocytoma
Phase 3 trial met one of two co-primary endpoints.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).
Phase 2 initiation of dosing announced June 13, 2019.
1095
Prostate Cancer

Latest News

  1. Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer,

  2. Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer

    NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer,

  3. Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ("Progenics" or the "Company"), an oncology company developing innovative targeted medicines and artificial intelligence to

  4. Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board

    Progenics Stockholders Consent to Removal of CEO Mark Baker, Dr. David Scheinberg and Nicole Williams and Election of All Five Velan Nominees – Gérard Ber, Eric Ende, Ann MacDougall, Heinz Mäusli and David Mims Velan

  5. Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

    Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical TherapeuticsAZEDRA Commercial Dosing

  6. Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board

    All Three Proxy Advisory Firms (Glass Lewis, ISS, and Egan Jones) Support Velan's Case for Change and Recommend Stockholders Vote on the GREEN Consent Card Glass Lewis Recommends Stockholders Vote FOR Dr. Gérard Ber,

  7. Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan's Nominees Control of the Board

    November 17 is the Only Deadline for Velan's Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 NEW YORK, Nov. 04,

  8. Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan's Consent Solicitation

    Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents Demanded by Velan

  9. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  10. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  11. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  12. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  13. Independent Director Candidates Nominated by Velan Issue Letter to Progenics Shareholders

    Today, Dr. Gérard Ber released an open letter to stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ:PGNX) on behalf of himself and the four other fully-independent director candidates

  14. Velan Responds to Misleading Communications from Progenics

    Progenics Has Again Resorted to False Information and Misleading Innuendo in Seemingly Desperate Attempt to Avoid Accountability and Deprive Stockholders of Chance to Realize Company's Full Value Velan Purchased

  15. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  16. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  17. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  18. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  19. Progenics Sends Letter to Shareholders

    Calls Out Velan's Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics' WHITE Consent Revocation Card NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) --

  20. Progenics Sends Letter to Shareholders

    Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders

  21. Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement

    Believes a Reconstituted Board is Immediately Needed to Reverse Strategic, Operational and Oversight Failures at the Company Urges Stockholders to Continue to Make their Voices Heard Following 2019 Annual Meeting

  22. PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to Lantheus

  23. Velan Comments on Announced Sale of Progenics to Lantheus

    Believes Company's Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard Views Progenics' Potential Value Under

  24. Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PGNX

    NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to Lantheus Holdings, Inc.

  25. Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

    Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus' Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the

  26. Progenics Confirms Notice of Preliminary Consent Solicitation by Velan Capital, L.P. Despite Repeated Efforts by the Company to Reach a Reasonable Resolution

    Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders No Shareholder Action Required at this Time NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,

  27. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current

  28. Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer,